These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
155 related items for PubMed ID: 22297114
1. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD. Shan WJ, Huang L, Zhou Q, Jiang HL, Luo ZH, Lai KF, Li XS. Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1523-6. PubMed ID: 22297114 [Abstract] [Full Text] [Related]
2. Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD. Liu A, Huang L, Wang Z, Luo Z, Mao F, Shan W, Xie J, Lai K, Li X. Bioorg Med Chem Lett; 2013 Mar 01; 23(5):1548-52. PubMed ID: 23375225 [Abstract] [Full Text] [Related]
3. Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors. Huang L, Shan W, Zhou Q, Xie J, Lai K, Li X. Bioorg Med Chem Lett; 2014 Jan 01; 24(1):249-53. PubMed ID: 24300734 [Abstract] [Full Text] [Related]
4. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist. Tannheimer SL, Sorensen EA, Cui ZH, Kim M, Patel L, Baker WR, Phillips GB, Wright CD, Salmon M. J Pharmacol Exp Ther; 2014 Apr 01; 349(1):85-93. PubMed ID: 24513870 [Abstract] [Full Text] [Related]
5. A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD. Jacobsen JR, Choi SK, Combs J, Fournier EJ, Klein U, Pfeiffer JW, Thomas GR, Yu C, Moran EJ. Bioorg Med Chem Lett; 2012 Jan 15; 22(2):1213-8. PubMed ID: 22178551 [Abstract] [Full Text] [Related]
6. The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD. Brown AD, Bunnage ME, Glossop PA, Holbrook M, Jones RD, Lane CA, Lewthwaite RA, Mantell S, Perros-Huguet C, Price DA, Webster R. Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6188-91. PubMed ID: 17897826 [Abstract] [Full Text] [Related]
7. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors. Taltavull J, Serrat J, Gràcia J, Gavaldà A, Córdoba M, Calama E, Montero JL, Andrés M, Miralpeix M, Vilella D, Hernández B, Beleta J, Ryder H, Pagès L. Eur J Med Chem; 2011 Oct 15; 46(10):4946-56. PubMed ID: 21871695 [Abstract] [Full Text] [Related]
9. Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-β₂-agonist for the treatment of chronic obstructive pulmonary disease. Osborne R, Clarke N, Glossop P, Kenyon A, Liu H, Patel S, Summerhill S, Jones LH. J Med Chem; 2011 Oct 13; 54(19):6998-7002. PubMed ID: 21863888 [Abstract] [Full Text] [Related]
17. GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells. Joshi T, Yan D, Hamed O, Tannheimer SL, Phillips GB, Wright CD, Kim M, Salmon M, Newton R, Giembycz MA. J Pharmacol Exp Ther; 2017 Feb 13; 360(2):324-340. PubMed ID: 27927912 [Abstract] [Full Text] [Related]